“Under Joanne’s leadership, bluebird has built a strong corporate
development team that has executed on significant deal flow, enhancing
our emerging immuno-oncology and severe genetic disease pipeline and
expanding our set of tools, technologies, capabilities and partners,”
said
“As bluebird continues to expand its research, development and commercial efforts, I’m motivated by the personal stories of those we are aiming to help with our portfolio of novel tools and technologies,” said Dr. Smith-Farrell. “I look forward to continuing to work with the entire bluebird team and our partners who have joined us in our meaningful efforts to recode opportunities in cell and gene therapy to tackle a range of unmet needs for patients.”
Joanne has been promoted to chief business officer after joining
bluebird in
About bluebird bio, Inc.
bluebird bio is pioneering gene therapy with purpose. From our
bluebird bio is a human company powered by human stories. We’re putting our care and expertise to work across a spectrum of disorders by researching cerebral adrenoleukodystrophy, sickle cell disease, transfusion-dependent β-thalassemia and multiple myeloma using three gene therapy technologies: gene addition, cell therapy and (megaTAL-enabled) gene editing.
bluebird bio has additional nests in
Follow bluebird bio on social media: @bluebirdbio,
LinkedIn,
Instagram
and
Forward-Looking Statements
This release contains “forward-looking statements” within the meaning
of the Private Securities Litigation Reform Act of 1995, including
statements regarding the advancement of, and anticipated development and
commercialization plans for, the Company’s product candidates. Any
forward-looking statements are based on management’s current
expectations of future events and are subject to a number of risks and
uncertainties that could cause actual results to differ materially and
adversely from those set forth in or implied by such forward-looking
statements. These risks and uncertainties include, but are not limited
to, the risks that results from our prior and ongoing clinical trials of
our product candidates will not continue or be repeated in our ongoing
or planned clinical trials; risks that the current or planned clinical
trials of our product candidates will be insufficient to support future
regulatory submissions or to support marketing approval in the U.S. and
EU and the risk that our product candidates will not be successfully
developed, approved or commercialized. For a discussion of other risks
and uncertainties, and other important factors, any of which could cause
our actual results to differ from those contained in the forward-looking
statements, see the section entitled “Risk Factors” in our most recent
Form 10-K as well as discussions of potential risks, uncertainties and
other important factors in our subsequent filings with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20190501005175/en/
Source: bluebird bio, Inc.
bluebird bio
Investors:
Elizabeth Pingpank, 617-914-8736
epingpank@bluebirdbio.com
Media:
Jenn Snyder, 617-448-0281
jsnyder@bluebirdbio.com